Ms. Christina Cameron reports

ANTIBE ANNOUNCES RESULTS OF 2023 ANNUAL MEETING

Antibe Therapeutics Inc. has released the results of its annual meeting of shareholders held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided in the attached table.

Voting results on all matters voted on at the meeting have been filed on SEDAR.

About Antibe Therapeutics Inc.

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulphide platform to develop next-generation therapies to target inflammation arising from a wide range of medical conditions. The company's current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with non-steroidal anti-inflammatory drugs (NSAIDs). Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today's NSAIDs for acute pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized pain indication. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.